Intravenous administration of the glycoprotein IIb-IIIa receptor antagonist 7E3 induces reperfusion of an acute thrombotic occlusion of the canine coronary artery

Thrombosis Research

Volumn 90, Issue 2, 1998, Pages 95-100

  Shetler, Timothy J ^a   Bailey, Blanche D ^a   Jakubowski, Joseph A ^a   Jackson, Charles V ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antibody; Fibrinolysis; Platelet aggregation inhibitors; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY THROMBOSIS; DOG; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HEART MUSCLE REPERFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBIN TIME;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ASPIRIN; BLOOD COAGULATION; COMBINED MODALITY THERAPY; CORONARY CIRCULATION; CORONARY THROMBOSIS; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HEPARIN; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; MALE; MICE; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0032522180     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00070-X     Document Type: Article

References (15)

1. EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
2. Gold H.K., Coller B.S., Yasuda T., Saito T., Fallon J.T., Guerrero J.L., Leinbach R.C., Ziskind A.A., Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation. 77:1988;670-677.
3. Yasuda T., Gold H.K., Fallon J.T., Leinbach R.C., Guerrero J.L., Scudder L.E., Kanke M., Shealy D., Ross M.J., Collen D. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest. 81:1988;1284-1291.
4. Anderson H.V., Kirkeeide R.L., Krishnaswami A., Weigelt L.A., Revana M., Weisman H.F., Willerson J.T. Cyclic flow variations after coronary angioplasty in humans. Clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody J Am Coll Cardiol. 23:1994;1031-1037.
5. Gold H.K., Garabedian H.D., Dinsmore R.E., Guerrero L.J., Cigarroa J.E., Palacios I.F., Leinbach R.C. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans Circulation. 95:1997;1755-1759.
6. Jackson C.V., Crowe V.G., Frank J.D., Wilson H.C., Coffman W.J., Utterback B.G., Jakubowski J.A., Smith G.F. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther. 261:1992;546-552.
7. Bates E.R., McGillem M.J., Mickelson J.K., Pitt B., Mancini G.B.J. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation. 84:1991;2463-2469.
8. Mickelson J.K., Simpson P.J., Cronin M., Homeister J.W., Laywell E., Kitzen J., Lucchesi B.R. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation. 81:1990;617-627.
9. Shetler T.J., Crowe V.G., Bailey B.D., Jackson C.V. Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis. Circulation. 94:1996;1719-1725.
10. Freidman M. The coronary thrombus. Its origin and fate Human Pathol. 2:1971;81-128.
11. Coller B.S. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as a conjunctive therapy for coronary artery thrombolysis. Coronary Artery Disease. 3:1992;1016-1029.
12. Coller B.S. Platelets and thrombolytic therapy. N Engl J Med. 322:1990;332-342.
13. Cox A.D., Devine D.V. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood. 83:1994;1006-1016.
14. Reverter J.C., Beguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced, thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis" J Clin Invest. 98:1996;863-874.
15. Weitz J.I., Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 86:1990;385-391.